Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Regado Biosciences's Enterprise Value is $20.07 Mil.
Regado Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2016 was $-60.16 Mil. Therefore, Regado Biosciences's EV-to-EBIT ratio for today is -0.33.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Regado Biosciences's Enterprise Value is $20.07 Mil.
Regado Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2016 was $-60.04 Mil. Therefore, Regado Biosciences's EV-to-EBITDA ratio for today is -0.33.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Regado Biosciences's Enterprise Value is $20.07 Mil.
Regado Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2016 was $1.17 Mil. Therefore, Regado Biosciences's EV-to-Revenue ratio for today is 17.23.
Regado Biosciences Enterprise Value Historical Data
The historical data trend for Regado Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regado Biosciences's Enterprise Value
For the Biotechnology subindustry, Regado Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regado Biosciences's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regado Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Regado Biosciences's Enterprise Value falls into.
Regado Biosciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Regado Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regado Biosciences (NAS:RGDO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Regado Biosciences's current Enterprise Value is $20.07 Mil.
Regado Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.16 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Regado Biosciences's current Enterprise Value is $20.07 Mil.
Regado Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.04 Mil.
Regado Biosciences's current Enterprise Value is $20.07 Mil.
Regado Biosciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regado Biosciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Regado Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Regado Biosciences (Regado Biosciences) Business Description
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGDO has been successfully added to your 